<DOC>
	<DOCNO>NCT00758199</DOCNO>
	<brief_summary>The objective study determine extension bromfenac BID monotherapy effective decreasing retinal thickening post cataract IOL placement surgery . No study exist long treat NSAID post cataract IOL placement surgery . Currently , NSAID therapy post IOL placement surgery conjunction steroid treatment , last approximately 3 week . This study design examine benefit extend NSAID monotherapy regard macular thicken incidence CME .</brief_summary>
	<brief_title>Determination Optimum Duration Treatment With Bromfenac ( Xibrom ) Eyedrops Following Cataract Surgery</brief_title>
	<detailed_description />
	<mesh_term>Cataract</mesh_term>
	<mesh_term>Bromfenac</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Male female &gt; 18 year age schedule undergo bilateral cataract surgery Patients systemic disease enrol ocular manifestation disease ( e.g . diabetic normal retinal exam ) Expected visual outcome BCVA &gt; [ great equal ] 20/30 postoperatively Ability provide inform consent , take study medication direct , likely complete study visit Known contraindication study medication component Required use ocular medication study medication study Significant AMD , epiretinal membrane , retinal vein occlusion , diabetic macular edema , macular disease predispose cystoid macular edema . Posterior capsule rupture , Vitreous loss surgery complication surgeon 's opinion , could reduce potential target visual outcome Anticipated need mechanical iris dilate device</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>